Specific JAK2 mutation (JAK2R683) and multiple gene deletions in down syndrome acute lymphoblastic leukemia

Blood

Volumn 113, Issue 3, 2009, Pages 646-648

  Kearney, Lyndal ^a   Castro, David Gonzalez De ^a   Yeung, Jenny ^a   Procter, Julia ^a   Horsley, Sharon W ^a   Minenori, Eguchi Ishimae ^a,b   Bateman, Caroline M ^a   Anderson, Kristina ^a   Chaplin, Tracy ^c   Young, Bryan D ^c   Harrison, Christine J ^d   Kempski, Helena ^e   So, Chi Wai E ^a   Ford, Anthony M ^a   Greaves, Mel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GROWTH FACTOR; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY 21; ANIMAL; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DOWN SYNDROME; GENE DELETION; HUMANS; JANUS KINASE 2; MICE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 60249086789     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-170928     Document Type: Article

References (24)

1. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child. 1957;94:289-293.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
3. Robison LL, Nesbit ME Jr, Sather HN, et al. Down syndrome and acute leukemia in children: a 10- year retrospective survey from Childrens Cancer Study Group. J Pediatr. 1984;105:235-242.
4. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
5. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
6. Shimada A, Xu G, Toki T, Kimura H, Hayashi Y, Ito E. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood. 2004;103:366.
7. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
8. Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103:3544-3546.
9. Wiemels JL, Zhang Y, Chang J, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia. 2005;19:415-419.
10. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104:307-313.
11. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia. 2005; 19:310-312.
12. Malinge S, Ben-Abdelali R, Settegrana C, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood. 2007;109:2202- 2204.
13. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
14. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
15. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673-683.
16. Mullighan CG, Goorha S, Radtke I, et al. Genome- wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446:758-764.
17. Tsuzuki S, Karnan S, Horibe K, et al. Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization. Cancer Sci. 2007;98:698-706.
18. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21:1258-1266.
19. Paulsson K, Cazier JB, Macdougall F, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A. 2008;105:6708-6713.
20. Horsley SW, Colman S, McKinley M, et al. Genetic lesions in a preleukemic aplasia phase in a child with acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2008;47:333-340.
21. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111: 1575-1583.
22. Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12:501-513.
23. Dai X, Chen Y, Di L, et al. Stat5 is essential for early B cell development but not for B cell maturation and function. J Immunol. 2007;179:1068- 1079.
24. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106:4043-4049.